The Fulham Shore Share Price (FUL)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
The Fulham Shore Plc	LSE:FUL	London	Ordinary Share	GB00B9F8VG44	ORD GBP0.01

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.10	-0.79%	12.50	246,018	11:50:56

Bid Price		Offer Price	High Price	Low Price	Open Price
12.00		13.00	12.60	12.50	12.60

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Travel & Leisure	63.99	1.43	0.10	125.0	71

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
16:29:22	O	100,000	12.50	GBX

Related Shares
Compass (CPG), Ryanair (RYA), St James House (SJH), Challenger Acquisitions (CHAL)

The Fulham Shore (FUL) Latest News

The Fulham Shore News

Date	Time	Source	Headline
17/7/2019	07:00	UKREG	Fulham Shore PLC (The) Holding(s) in Company
16/7/2019	10:25	ALNC	Fulham Shore Swings To Annual Profit On Strong Trading; Eyes Payout
16/7/2019	07:38	ALNCF	Alliance News Flash Headline
16/7/2019	07:00	UKREG	Fulham Shore PLC (The) Final Results
27/6/2019	16:41	UKREG	Fulham Shore PLC (The) Second Price Monitoring Extn
27/6/2019	16:35	UKREG	Fulham Shore PLC (The) Price Monitoring Extension
28/3/2019	09:40	ALNC	Fulham Shore Guides For Revenue And Earnings Ahead Of Prior Year
28/3/2019	07:02	UKREG	Fulham Shore PLC (The) Year End Trading Update
07/1/2019	15:40	UKREG	Fulham Shore PLC (The) Director/PDMR Shareholding
12/12/2018	09:43	ALNC	Fulham Shore Shares Soar As Good Interim Results Spark New Openings

More The Fulham Shore News

The Fulham Shore Takeover Rumours

The Fulham Shore (FUL) Share Charts

1 Year The Fulham Shore Chart

1 Month The Fulham Shore Chart

Intraday The Fulham Shore Chart

The Fulham Shore (FUL) Discussions and Chat

The Fulham Shore Forums and Chat

Date	Time	Title	Posts
17/7/2019	00:11	The Fulham Shore PLC	188
26/7/2012	20:58	Fulcrum Pharma - drug development to regulatory approval (1.1.07)	631
21/2/2007	07:41	FULCRUM IN PROFIT & GROWING	1,807
17/4/2004	19:56	Strong buy - FUL Pharma - profit and turnover up x 10 fold	13
01/5/2003	09:14	Fulcrum Pharma (FUL)	1,061

Add a New Thread

The Fulham Shore (FUL) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-07-18 16:29:23	12.50	100,000	12,500.00	O
2019-07-18 14:48:24	12.58	11,881	1,494.04	O
2019-07-18 11:19:50	12.60	3,000	378.00	O
2019-07-18 09:33:20	12.62	1,485	187.47	O
2019-07-18 09:08:30	12.62	9,802	1,237.45	O

View all The Fulham Shore trades in real-time

The Fulham Shore (FUL) Top Chat Posts

Date	Subject
18/7/2019 09:20	The Fulham Shore Daily Update: The Fulham Shore Plc is listed in the Travel & Leisure sector of the London Stock Exchange with ticker FUL. The last closing price for The Fulham Shore was 12.60p. The Fulham Shore Plc has a 4 week average price of 10.15p and a 12 week average price of 10.15p. The 1 year high share price is 13.25p while the 1 year low share price is currently 8.75p. There are currently 570,269,265 shares in issue and the average daily traded volume is 295,485 shares. The market capitalisation of The Fulham Shore Plc is £71,283,658.13. Read Full Thread Reply
14/11/2018 11:14	investorschampion: The operator of Franco Manca and Real Greek restaurants has seen its share price tumble like many others in the dining out sector. While the Group’s restaurants appear to go down well with diners, we are less impressed with other aspects of the listed vehicle as our latest research on our website reveals. Read Full Thread Follow Reply
06/9/2017 11:21	lbo: http://uk.businessinsider.com/fulham-shore-share-price-franco-manca-profit-warning-sector-wide-slowdown-2017-9?r=US&IR=T Read Full Thread Follow Reply
01/7/2017 08:26	topvest: Yes, maybe you are correct. It's definitely appealing to the young. It wasn't packed in Bournemouth on a Friday evening though. Surely, you can't deny that the valuation is a bit crazy at £109m? It should be making £5-10m of profits to have that sort of valuation. 50 or so restaurants and break even ish profitability doesn't merit that valuation at all. Barriers to entry are also rather low. Needs at least 2 years of growth to grow into its existing share price. Any disappointment and the shares will get hammered. Read Full Thread Follow Reply
04/4/2017 07:52	utsushi: My penny's worth view-operationally the trading update was solid, earnings growth set to continue, the number of Franco Manca sites to increase to 45 by 2018, +50%, throwing off plenty of net cash, but high CAPEX, management good in Mr.Page, however valuation full, 13x EBITDA near term. Long term future positive for the company, but valuation risk if we enter a consumer lead down turn. The share price has a muted, positive tone, could drift higher-limited upside. No position-just a "ghost gambler". Read Full Thread Follow Reply
07/11/2016 17:25	lbo: Tasty PLC just did a large fundraising which explains why it's share price has been falling all year. Is the same on the cards here? Read Full Thread Follow Reply
28/4/2010 07:36	welsheagle: RNS Number : 9149K Fulcrum Pharma PLC 28 April 2010 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY RESTRICTED JURISDICTION (INCLUDING THE UNITED STATES, AUSTRALIA, CANADA AND JAPAN) OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 28 April 2010 RECOMMENDED CASH OFFER by GOLD MEDAL ACQUISITIONS UK LIMITED for FULCRUM PHARMA PLC Summary · The boards of Gold Medal Acquisitions UK Limited ("Gold Medal UK") and Fulcrum Pharma plc ("Fulcrum Pharma" or the "Company") are pleased to announce the terms of a recommended cash offer, to be made by Gold Medal UK for the entire issued and to be issued share capital of Fulcrum Pharma (the "Offer"). · The Offer will comprise 5.85 pence in cash for each Fulcrum Pharma Share (the "Offer Price"). · The Offer values the entire issued and to be issued share capital of Fulcrum Pharma at approximately £11.56 million. · The Offer Price represents a premium of approximately: o 73 per cent. to the Closing Price of 3.375 pence per Fulcrum Pharma Share on 27 April 2010, being the last Business Day prior to this Announcement; and o 83 per cent. to the average Closing Price of 3.20 pence per Fulcrum Pharma Share for the six month period ended 27 April 2010, being the last Business Day prior to this Announcement. · The Independent Directors, who have been so advised by Singer Capital Markets, consider the terms of the Offer to be fair and reasonable. In providing advice to the Independent Directors, Singer Capital Markets has taken into account the commercial assessments of the Independent Directors. · Accordingly, the Independent Directors intend unanimously to recommend that Fulcrum Pharma Shareholders accept the Offer. · The Fulcrum Pharma Directors have irrevocably undertaken with Gold Medal UK to accept, or procure the acceptance of, the Offer in respect of their entire beneficial holdings of Fulcrum Pharma Shares, which amount in aggregate to 11,114,563 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 6.25 per cent. of the current issued share capital of Fulcrum Pharma and in respect of any Fulcrum Pharma Shares that may be issued to, or acquired by, them pursuant to the exercise of options they hold over Fulcrum Pharma Shares. · Certain other Fulcrum Pharma Shareholders (not being Fulcrum Pharma Directors) have irrevocably undertaken to accept, or procure the acceptance of, the Offer in respect of certain of their respective beneficial holdings of Fulcrum Pharma Shares which amount, in aggregate, to 45,161,603 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 25.38 per cent. of the current issued share capital of Fulcrum Pharma. · In total, Fulcrum Pharma Shareholders have undertaken to accept, or procure the acceptance of, the Offer in respect of, in aggregate, 56,276,166 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 31.63 per cent. of the current issued share capital of Fulcrum Pharma. · Commenting on the Offer, Patrick K Donnelly (Executive Chairman of Gold Medal UK) said: "We are very excited about teaming up with the staff and management at Fulcrum Pharma due to their high level of expertise in drug development, regulatory submissions, drug safety services and consulting. In tandem with new capital from SV Life Sciences and The Halifax Group we look forward to significantly expanding the service offerings and geographic breadth of the Company as well as the career opportunities of the team." · Commenting on the Offer, Grahame Cook, Non-Executive Chairman of Fulcrum Pharma, said: "The acquisition of Fulcrum Pharma by Gold Medal UK is in the best interests of Fulcrum Pharma shareholders. Our small market capitalisation and our inflexible shareholder structure mean that there is very little liquidity in Fulcrum Pharma's shares and our share price is unlikely to reflect the company's value in the foreseeable future. We would like to make a number of identified acquisitions to add critical mass and expand our service offering. We have been unable to achieve the required equity funding from the stock market despite considerable efforts to do so. SV Life Sciences and The Halifax Group, Gold Medal UK's funders, are prepared to support this growth strategy. We have for these reasons concluded that the Offer, which represents a substantial premium to the current share price, is in the best interests of shareholders." This summary should be read in conjunction with, and is subject to, the full text of the following announcement (including the Appendices). The Offer will be subject to the Conditions and further terms set out in Appendix 1 to the following announcement and the terms and conditions to be set out in the Offer documentation, when issued. Appendix 2 contains the sources and bases of certain information used in this summary and in the following announcement. Appendix 3 contains definitions of certain terms used in this summary and the following announcement. Read Full Thread Follow Reply
28/4/2010 07:31	welsheagle: Day prior to this Announcement; and o 83 per cent. to the average Closing Price of 3.20 pence per Fulcrum Pharma Share for the six month period ended 27 April 2010, being the last Business Day prior to this Announcement. · The Independent Directors, who have been so advised by Singer Capital Markets, consider the terms of the Offer to be fair and reasonable. In providing advice to the Independent Directors, Singer Capital Markets has taken into account the commercial assessments of the Independent Directors. · Accordingly, the Independent Directors intend unanimously to recommend that Fulcrum Pharma Shareholders accept the Offer. · The Fulcrum Pharma Directors have irrevocably undertaken with Gold Medal UK to accept, or procure the acceptance of, the Offer in respect of their entire beneficial holdings of Fulcrum Pharma Shares, which amount in aggregate to 11,114,563 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 6.25 per cent. of the current issued share capital of Fulcrum Pharma and in respect of any Fulcrum Pharma Shares that may be issued to, or acquired by, them pursuant to the exercise of options they hold over Fulcrum Pharma Shares. · Certain other Fulcrum Pharma Shareholders (not being Fulcrum Pharma Directors) have irrevocably undertaken to accept, or procure the acceptance of, the Offer in respect of certain of their respective beneficial holdings of Fulcrum Pharma Shares which amount, in aggregate, to 45,161,603 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 25.38 per cent. of the current issued share capital of Fulcrum Pharma. · In total, Fulcrum Pharma Shareholders have undertaken to accept, or procure the acceptance of, the Offer in respect of, in aggregate, 56,276,166 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 31.63 per cent. of the current issued share capital of Fulcrum Pharma. · Commenting on the Offer, Patrick K Donnelly (Executive Chairman of Gold Medal UK) said: "We are very excited about teaming up with the staff and management at Fulcrum Pharma due to their high level of expertise in drug development, regulatory submissions, drug safety services and consulting. In tandem with new capital from SV Life Sciences and The Halifax Group we look forward to significantly expanding the service offerings and geographic breadth of the Company as well as the career opportunities of the team." · Commenting on the Offer, Grahame Cook, Non-Executive Chairman of Fulcrum Pharma, said: "The acquisition of Fulcrum Pharma by Gold Medal UK is in the best interests of Fulcrum Pharma shareholders. Our small market capitalisation and our inflexible shareholder structure mean that there is very little liquidity in Fulcrum Pharma's shares and our share price is unlikely to reflect the company's value in the foreseeable future. We would like to make a number of identified acquisitions to add critical mass and expand our service offering. We have been unable to achieve the required equity funding from the stock market despite considerable efforts to do so. SV Life Sciences and The Halifax Group, Gold Medal UK's funders, are prepared to support this growth strategy. We have for these reasons concluded that the Offer, which represents a substantial premium to the current share price, is in the best interests of shareholders." This summary should be read in conjunction with, and is subject to, the full text of the following announcement (including the Appendices). The Offer will be subject to the Conditions and further terms set out in Appendix 1 to the following announcement and the terms and conditions to be set out in the Offer documentation, when issued. Appendix 2 contains the sources and bases of certain information used in this summary and in the following announcement. Appendix 3 contains definitions of certain terms used in this summary and the following announcement. Read Full Thread Follow Reply
19/1/2010 15:36	ianctaylor: I considered buying shares in this company today but decided not to in the end. The share price is not stable enough for me. I prefer to see a smoother, more consistent price movement. I hope the preliminary approach made to the company in mid-November 2009 results in some benefit to holders. For what it's worth, a fair value per share would seem to be about 7p, with 177,940,743 shares in issue. Read Full Thread Follow Reply
14/7/2009 14:54	gimeabreak: Had a feeling the share price would hike soon it had crashed without justification so just getting back to a semblance of its true value, that spread though has prevented me from buying more so so frustrating. Read Full Thread Follow Reply
24/6/2009 19:15	gimeabreak: Nice one scruff if only if only. Really though if you read through the final results they appear quite positive when other companies are in financial difficulties laying off staff going bust Fulcrums performance is very good,which makes me wonder why the share price has taken such a battering as trading in this stock has been none existant nobody buying nobody selling, some hidden agenda whatever, I've held this stock for years and years never seen a profit, looks like another few more are to come before I'm rich rich RICH RICH HHHAAAAAA YIKKKEEESSSSSSS another tablet please doc Read Full Thread Follow Reply

The Fulham Shore share price data is direct from the London Stock Exchange

Your Recent History

LSE

FUL

The Fulham..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190719 02:12:39